Oppenheimer Raises Corbus Pharmaceuticals (NASDAQ:CRBP) Pric

Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) had its price objective increased by Oppenheimer from $20.00 to $51.00 in a research note published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Separately, StockNews.com started coverage on shares of Corbus Pharmaceuticals in a research report on Friday, January 26th. They […]

Related Keywords

, Corbus Pharmaceuticals Holdings Inc , Corbus Pharmaceuticals , Institutional Investors Weigh In On Corbus Pharmaceuticals , Corbus Pharmaceuticals Company Profile , Corbus Pharmaceuticals Trading , News Ratings For Corbus Pharmaceuticals Daily , Vident Investment Advisory , Securities Exchange Commission , Renaissance Technologies , Dimensional Fund Advisors , Free Report , Get Free Report , Cormorant Asset Management , Exchange Commission , Sigma Investments , Fund Advisors , Investment Advisory , Street Corp , Pharmaceuticals Holdings , Corbus Pharmaceuticals Daily , Nasdaq Crbp , Crbp , Medical , Boost Price Target , Oppenheimer Holdings Inc ,